Atara Biotherapeutics to Participate at Three Upcoming Investor Conferences
November 08 2021 - 4:01PM
Business Wire
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell
immunotherapy, leveraging its novel allogeneic Epstein-Barr virus
(EBV) T-cell platform to develop transformative therapies for
patients with cancer and autoimmune diseases, today announced that
Pascal Touchon, President and Chief Executive Officer of Atara,
will participate at three upcoming virtual conferences.
Cowen 5th Annual IO Next Summit Fireside chat on Monday,
November 15, 2021 at 9:45 a.m. EST
Stifel 2021 Virtual Healthcare Conference Fireside chat
on Monday, November 15, 2021 at 4:40 p.m. EST
Evercore ISI 4th Annual HealthCONx Virtual Conference
Fireside chat on Tuesday, November 30, 2021 at 10:05 a.m. EST
Live video webcasts will be available by visiting the Investor
Events and Presentations section of atarabio.com. Archived replays
will be available on the Company's website for 30 days following
the live webcasts.
About Atara Biotherapeutics, Inc. Atara Biotherapeutics,
Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging
its novel allogeneic EBV T-cell platform to develop transformative
therapies for patients with serious diseases including solid
tumors, hematologic cancers and autoimmune disease. With our lead
program in Phase 3 clinical development, Atara is the most advanced
allogeneic T-cell immunotherapy company and intends to rapidly
deliver off-the-shelf treatments to patients with high unmet
medical need. Our platform leverages the unique biology of EBV T
cells and has the capability to treat a wide range of
EBV-associated diseases, or other serious diseases through
incorporation of engineered CARs (chimeric antigen receptors) or
TCRs (T-cell receptors). Atara is applying this one platform, which
does not require TCR or HLA gene editing, to create a robust
pipeline including: tab-cel® in Phase 3 development for
Epstein-Barr virus-driven post-transplant lymphoproliferative
disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell
immunotherapy targeting EBV antigens as a potential treatment for
multiple sclerosis; and multiple next-generation chimeric antigen
receptor T-cell (CAR T) immunotherapies for both solid tumors and
hematologic malignancies. Improving patients’ lives is our mission
and we will never stop working to bring transformative therapies to
those in need. Atara is headquartered in South San Francisco and
our leading-edge research, development and manufacturing facility
is based in Thousand Oaks, California. For additional information
about the company, please visit atarabio.com and follow us on
Twitter and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211108006021/en/
INVESTORS & MEDIA: Investors Eric Hyllengren
805-395-9669 ehyllengren@atarabio.com
Media Alex Chapman 805-456-4772 achapman@atarabio.com
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From May 2024 to Jun 2024
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Jun 2023 to Jun 2024